Name | 2-hydroxy-N-[2-[3-methyl-2-oxo-7-[[3-(trifluoromethyl)phenyl]methylamino]quinoxalin-1-yl]ethyl]acetamide |
---|---|
Synonyms | unii-oh3j29q653 |
Description | CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC50s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively. |
---|---|
Related Catalog | |
Target |
IC50: 38 nM (rat microsomal), 6.1 nM (human HEPG2)[1][2]. |
In Vitro | CVT-12012 (Compound 5b) displays the highest potency in both the microsomal and the HEPG2 SCD assays (IC50 38 nM and 6.1 nM, respectively) compared to the other methyl-substituted compounds[1]. |
In Vivo | In a rat PK study, CVT-12012 demonstrates good oral bioavailability (78%). It appears that the oral absorption of CVT-12012 is not affected by a significant Pgp efflux, which is expected based on Caco-2 assay result. The plasma clearance of CVT-12012 is high (88 mL/min/kg) with elimination half-life of approximately 1 h[1]. |
References |
Molecular Formula | C21H21F3N4O3 |
---|---|
Molecular Weight | 434.41200 |
Exact Mass | 434.15700 |
PSA | 99.74000 |
LogP | 3.35760 |
Storage condition | 2-8℃ |
Precursor 1 | |
---|---|
DownStream 0 |